Published online before print September 6, 2005, doi: 10.1161/CIRCULATIONAHA.105.538272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1580-1586.)
© 2005 American Heart Association, Inc.
Heart Failure |
Left Ventricular Reverse Remodeling but Not Clinical Improvement Predicts Long-Term Survival After Cardiac Resynchronization Therapy
From the Division of Cardiology (C.-M.Y., J.W.-H.F., Q.Z., Y.-S.C., S.-L.K.), Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, and the Department of Cardiology (G.B.B., M.J.S., E.E.v.d.W., J.J.B.), Leiden University Medical Center, Leiden, the Netherlands.
Reprint requests to Prof Cheuk-Man Yu, Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, NT, Hong Kong. E-mail cmyu{at}cuhk.edu.hk
Received January 24, 2005; revision received June 16, 2005; accepted June 20, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— In patients with severe heart failure and dilated cardiomyopathy, cardiac resynchronization therapy (CRT) improves left ventricular (LV) systolic function associated with LV reverse remodeling and favorable 1-year survival. However, it is unknown whether LV reverse remodeling translates into a better long-term prognosis and what extent of reverse remodeling is clinically relevant, which were investigated in this study.
Methods and Results— Patients (n=141) with advanced heart failure (mean±SD age, 64±11 years; 73% men) who received CRT were followed up for a mean (±SD) of 695±491 days. The extent of reduction in LV end-systolic volume (LVESV) at 3 to 6 months relative to baseline was examined for its predictive value on long-term clinical outcome. The cutoff value for LV reverse remodeling in predicting mortality was derived from the receiver operating characteristic curve. Then the relation between potential predictors of mortality and heart failure hospitalizations were compared by Kaplan-Meier survival analysis, followed by Cox regression analysis. There were 22 (15.6%) deaths, mostly due to heart failure or sudden cardiac death. The receiver operating characteristic curve found that a reduction in LVESV of 
9.5% had a sensitivity of 70% and specificity of 70% in predicting all-cause mortality and of 87% and 69%, respectively, for cardiovascular mortality. With this cutoff value, there were 87 (61.7%) responders to reverse remodeling. In Kaplan-Meier survival analysis, responders had significantly lower all-cause morality (6.9% versus 30.6%, log-rank 
2=13.26, P=0.0003), cardiovascular mortality (2.3% versus 24.1%, log-rank 2=17.1, P<0.0001), and heart failure events (11.5% versus 33.3%, log-rank 2=8.71, P=0.0032) than nonresponders. In the Cox regression analysis model, the change in LVESV was the single most important predictor of all-cause (ß=1.048, 95% confidence interval=1.019 to 1.078, P=0.001) and cardiovascular (ß=1.072, 95% confidence interval=1.033 to 1.112, P<0.001) mortality. Clinical parameters were unable to predict any outcome event.
Conclusions— A reduction in LVESV of 10% signifies clinically relevant reverse remodeling, which is a strong predictor of lower long-term mortality and heart failure events. This study suggests that assessing volumetric changes after an intervention in patients with heart failure provides information predictive of natural history outcomes.
Key Words: pacing • prognosis • heart failure • echocardiography • mortality
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cardiac resynchronization therapy (CRT) is an established treatment for patients with advanced chronic heart failure with electromechanical delay.1–4 Apart from the beneficial effects of CRT on symptoms and exercise capacity, left ventricular (LV) reverse remodeling5,6 and improvement in clinical outcome were also observed in large, multicenter clinical trials.2,4 Whether the observed LV reverse remodeling is clinically relevant is unclear.
However, large heart failure trials demonstrated that drug therapy that limited or reversed LV remodeling resulted in improved long-term survival.7 In those studies, LV end-systolic volume (LVESV) was the strongest predictor of survival among clinical and echocardiographic parameters.8 For example, in the multicenter trials of angiotensin-converting enzyme (ACE) inhibitors (eg, the SAVE study), LV volumes were strong predictors of long-term mortality and cardiovascular events, independent of the effect of the ACE inhibitor captopril.9 The extent of LV reverse remodeling after CRT was reported to be a >20% reduction in LVESV, which is much larger than that observed in medical therapy for heart failure.10–12 This phenomenon was observed in the first 3 to 6 months after CRT. Because the mechanism of benefit of device therapy is somewhat different from that of medical therapy, it is currently unclear whether the LV reverse remodeling observed in patients undergoing CRT is predictive of improved long-term clinical outcome. Moreover, what extent of LV reverse remodeling is needed to result in improved survival is also unclear. Therefore, the aims of the current study were (1) to examine whether the LV reverse remodeling observed at 3 to 6 months is associated with better long-term clinical outcome in heart failure patients who received CRT and (2) to determine what extent of LV reverse remodeling predicts improved outcome in this population.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients
This is a prospective, follow-up study that involved 2 university hospitals. The study population included 141 heart failure patients (mean±SD age, 64±11 years; 73% men) who underwent CRT and had a baseline and a 3- to 6-month follow-up echocardiographic study to assess potential LV reverse remodeling. The inclusion criteria included severe symptomatic heart failure despite optimized medical therapy, LV systolic dysfunction with an LV ejection fraction (EF) <40%, and QRS duration >120 ms. Serial echocardiographic studies with tissue Doppler imaging (TDI) were performed before and 3 to 6 months after CRT to assess LV reverse remodeling. These patients had been prescribed optimal medical therapy before consideration for CRT. Medication use was unchanged within the first 6 months of CRT, and any changes afterward were avoided unless clinically mandatory. Clinical assessments were also performed at the same times, including New York Heart Association (NYHA) class, Minnesota Living With Heart Failure quality-of-life questionnaire, and a 6-minute hall-walk distance. Two patients died (1 refractory heart failure, 1 sudden cardiac death) before the 3- to 6-month echocardiographic follow-up; therefore, data for these patients were excluded from the current analysis. The study was approved and conducted in compliance with the regulations of the local ethics committees of both institutions, and informed consent was obtained from all patients.
Pacemaker Implantation
CRT devices were implanted as previously described.10,13 The LV pacing lead was inserted by a transvenous approach through the coronary sinus into either the lateral or posterolateral cardiac vein whenever possible. All patients who received CRT devices had biventricular stimulation of the heart with implantation of right ventricular leads.
Echocardiography
Standard echocardiography, including TDI studies, was performed with commercially available equipment (Vivid 7, GE Vingmed Ultrasound). The LV end-diastolic volume (LVEDV), LVESV, and LV EF were assessed by the biplane Simpson’s equation in apical 4-chamber and 2-chamber views. The intraobserver and interobserver variabilities for volumetric assessment were 4% and 5%, respectively.12 The severity of mitral regurgitation was assessed by the percentage jet area relative to left atrial size in the apical 4-chamber view. At least 3 consecutive beats of sinus rhythm were measured, and the mean was calculated.
TDI was performed in the apical 4-chamber view for long-axis motion of the ventricle, as previously described.5,10,14,15 Two-dimensional echocardiography with TDI color-imaging views was optimized for pulse repetition frequency, color saturation, sector size, and depth, allowing the highest possible frame rate. At least 3 consecutive beats were stored, and the images were analyzed off-line with a customized software package (EchoPac 6.1 for PC, GE Vingmed Ultrasound). The myocardial velocity curves were constructed off-line, and the septal-to-lateral delay at the basal segments was measured as an index of systolic dyssynchrony, with the beginning of the QRS complex as the reference point.14,15
Long-Term Follow-Up and Assessment of Cardiovascular Events
All patients were followed up regularly (typically every 2 to 3 months) in the heart failure clinic, with regular clinical assessment, ECG, and device interrogation to ensure that biventricular pacing was being maintained. Only outcomes occurring after the 3- to 6-month follow-up echocardiograms were related to echocardiographic changes in LV volume. The occurrence of cardiovascular events was adjudicated by cardiologists blinded to the echocardiographic findings. The cause of death was ascertained by reviewing the clinical record and test results, report of close relatives, and postmortem findings. For cardiovascular hospitalization, the diagnosis of heart failure was based on clinical symptoms (limitation of activity, fatigue, and dyspnea or orthopnea), physical signs (edema, elevated jugular venous pressure, rales, or third heart sound with gallop), or radiological evidence of pulmonary congestion.16 Acute coronary syndrome was defined according to current guidelines based on the presence of typical chest pain or discomfort and elevation of cardiac enzymes, such as creatine kinase-MB, troponin I, or troponin T. ECG changes were not used as a criterion, because these patients had baseline left bundle branch block and subsequent ventricular pacing, which hampers assessment of myocardial ischemia or infarction.
Statistical Analysis
Results are presented as mean±SD. Data were compared with paired or unpaired Student t test when appropriate. Comparison of proportions was performed by 2 analysis with Yates’ correction. Receiver-operating-characteristic (ROC) curves were analyzed to assess the best cutoff value of LVESV to predict mortality. Life table–estimated actuarial survival was calculated by Kaplan-Meier curves, wherein the log-rank 2 values were presented. Cox regression multivariable survival analysis was used to evaluate the predictive value of multiple factors on mortality. The data from patients in this dataset have not been published previously. P<0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Among 141 patients, 12 were in NYHA class II, 106 in class III, and 23 in class IV. The cause of heart failure was ischemic in 68 (48%) and nonischemic in 73 (52%) patients. Medications included diuretics in nearly all patients, ACE inhibitors or angiotensin receptor blockers in 91%, ß-blockers in 75%, spironolactone in 49%, and digoxin in 16%. Echocardiographic studies demonstrated LV reverse remodeling 3 to 6 months after CRT. The LVESV decreased significantly by 17.6±18.4% (P<0.001), whereas LVEDV decreased by 11.0±14.3% (P<0.001). LV EF increased by 6.3±6.9% (P<0.001).
Clinical Outcome of Patients During Long-Term Follow-Up
The mean duration of follow-up was 695±491 days (range, 90 to 1992). There were 22 (15.6%) deaths. The causes of death included heart failure in 9 patients, sudden cardiac death in 6, myocardial infarction in 1, cerebrovascular accident in 1, and noncardiac-related deaths in 5; thus, 17 patients died of cardiovascular causes. Table 1 compares the clinical and echocardiographic parameters between survivors and those who died during follow-up. All baseline characteristics were comparable except for a slightly higher mean NYHA class in the patients who died during follow-up. Also, the extent of LV dyssynchrony at baseline was larger in the survivors. The reduction in clinical parameters (NYHA class, quality-of-life score, and 6-minute walking distance) tended to improve more in survivors, although the differences were not statistically significant. The extent of LV reverse remodeling and improvement in LV EF were significantly larger in survivors. The mean reduction in LVESV in survivors was 19.8±17.7% compared with 5.9±18.0% (P=0.001) in those who died during follow-up; the mean reduction of LVEDV in survivors was 12.4±14.2% versus 3.0±12.6% (P=0.004) in the patients who died during follow-up. Nineteen patients were hospitalized for decompensated heart failure. Twenty-one were hospitalized for other cardiovascular causes, including acute coronary syndrome in 7, arrhythmias in 11, stroke in 2, and percutaneous coronary intervention in 1.
|
What Extent of LV Reverse Remodeling Predicts Survival?
This study attempted to determine a clinically useful cutoff value for the change in LVESV to assess whether LV reverse remodeling after CRT can predict a favorable long-term clinical outcome. Based on ROC curve analysis, a reduction in LVESV of 9.5% was identified as the optimal cutoff value to predict long-term survival (area under the curve [AUC], 0.711; P=0.002; see Figure 1A). With this cutoff value, a sensitivity and specificity of 70% were obtained to predict all-cause mortality. Similarly, a reduction in LVESV of 9.5% had a sensitivity and specificity of 87% and 69%, respectively, to predict cardiovascular mortality (AUC, 0.774; P=0.001; see Figure 1B). Furthermore, the change in LVESV was consistently better than the change in LVEDV in predicting all-cause and cardiovascular mortality (Figure 1A and 1B). The AUCs for LVEDV to predict all-cause and cardiovascular mortality were 0.688 (P=0.005) and 0.720 (P=0.005), respectively.
|
LV Reverse Remodeling After CRT and Prediction of Long-Term Prognosis
Based on the aforementioned findings, a reduction in LVESV of 10% was used as the cutoff value to define patients with clinically relevant LV reverse remodeling. There were 87 (61.7%) patients with a reduction in LVESV of 10% (called "responders") and 54 (38.3%) patients with <10% reduction in LVESV (called "nonresponders"). During long-term follow-up, 81 of 87 (93.1%) responders to LV reverse remodeling survived, compared with only 38 of 54 (70.4%) nonresponders (2=13.1, P<0.001). Kaplan-Meier life-table survival analysis demonstrated that responders to LV reverse remodeling had significantly lower all-cause mortality (n=22 who had the censored event, 6.9% versus 30.6%; log-rank 2=13.26, P=0.0003; Figure 2A) and cardiovascular mortality (n=17, 2.3% versus 24.1%; log-rank 2=17.1, P<0.0001) compared with nonresponders. Furthermore, patients with reverse remodeling had a lower rate of heart failure events (both fatal and nonfatal; n=28, 11.5% versus 33.3%; log-rank 2=8.71, P=0.0032; Figure 2B), all-cause mortality or heart failure hospitalization (n=33 who had the censored event, 13.8% versus 38.9%, log-rank 2=9.92, P=0.0016) (Figure 2C), and the composite end point of all-cause mortality or cardiovascular hospitalization (n=54 who had the censored event, 29.1% versus 55.8%; log-rank 2=9.18, P=0.0025).
|
Baseline assessment of LV dyssynchrony was also compared with long-term survival. It was observed that survival was associated with significantly more severe dyssynchrony (P<0.001) (Table 1). Patients who had a baseline dyssynchrony >60 ms had a lower all-cause mortality (6.6% versus 21.8%; log-rank 2=4.46, P=0.03).
Clinical parameters were evaluated for their predictive value for mortality. However, only NYHA class at baseline was significantly higher (P=0.038) in those who died. There was no difference in 6-minute hall-walk distance or quality-of-life score between the 2 groups or the changes in these parameters 3 to 6 months after CRT (Table 1). Therefore, clinical parameters of heart failure assessment were unable to predict long-term outcome in these patients.
The predictive value of clinical/echocardiographic parameters for all-cause mortality was compared by the Cox regression multivariable analysis model. It was found that the reduction in LVESV was the only independent predictor of all-cause mortality (ß=1.048, 95% confidence interval=1.019 to 1.078, P=0.001) (Table 2) and cardiovascular mortality (ß=1.072, 95% confidence interval=1.033 to 1.112, P<0.001), whereas LV dyssynchrony at baseline, cause (ischemic versus nonischemic), and other clinical or echocardiographic parameters listed in Table 1 were insignificant.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study examined the relation between LV reverse remodeling and long-term clinical outcome. Patients who died during follow-up exhibited less LV reverse remodeling compared with survivors. Based on the ROC curve, a cutoff value of <10% reduction in LVESV yielded the best prediction of all-cause and cardiovascular mortality. In addition to LV reverse remodeling, baseline LV dyssynchrony was predictive of survival. On multivariable analysis, however, LV reverse remodeling was the best predictor of long-term survival. Of note, improvement in clinical status 3 to 6 months after CRT was not predictive of long-term clinical outcome.
Definition of LV Reverse Remodeling After CRT and Its Prognostic Significance
Previous studies reported that CRT not only improves clinical status (NYHA class, quality of life, and exercise capacity)1,2,4 but also reverses LV remodeling and improves systolic function.6,10,11 However, the lack of a favorable response to CRT was observed in approximately one third of patients in clinical studies. The definition of nonresponders is difficult but has been proposed to be the lack of a clinical response or the absence of LV reverse remodeling.2,10,11,17 Initial studies arbitrarily defined responders to LV reverse remodeling by a reduction in LVESV of >15% 3 to 6 months after CRT.10,11 However, no study examined the potential link between LV reverse remodeling and long-term clinical outcome, and it was not known whether such an arbitrarily defined cutoff value of 15% was clinically relevant. Because improvement in LVESV represents favorable structural and functional changes in the LV after CRT, this may predict a favorable long-term clinical outcome. In pharmacological trials, LV reverse remodeling (in particular, a reduction of LVESV) was associated with a better prognosis, in particular in clinical trials with ACE inhibitors and ß-blockers.9,18,19 Because CRT benefits cardiac function by a different mechanism from that which primarily involves coordination of regional contraction, rather than direct intervention in neurohormonal pathways,10,14 the possibility that a reduction in LV volume in patients who receive CRT would predict better long-term clinical outcome has not been explored.
The present study is the largest to directly examine the relation between LV reverse remodeling and outcomes in patients with heart failure in the contemporary treatment era. A new cutoff value derived from the ROC curves of mortality prediction concluded that a reduction in LVESV of 10% was clinically relevant, because this value has a high sensitivity and specificity for prediction of long-term all-cause and cardiovascular mortality. Furthermore, this cutoff value of LV reverse remodeling also predicts heart failure events and composite end points of cardiovascular hospitalization or mortality. Therefore, volumetric assessment by echocardiography is not only a surrogate marker of a favorable cardiac response to CRT but also an objective measure that predicts long-term clinical outcome.
Lack of Predictive Value of Clinical Parameters on Long-Term Outcome
Another important observation in the current study is the lack of predictive value of baseline clinical status or change in clinical status after CRT on long-term clinical outcome. The clinical parameters in the present study included NYHA class, 6-minute hall-walk distance, and quality-of-life score. These parameters are frequently used as standard "soft" clinical end points for assessment of treatment efficacy in heart failure trials, including CRT,1–4 and have been used as criteria to assess "clinical" response to CRT.20 However, in the present study, improvements in quality of life and walking distance were not significantly different between those who survived and those who died during long-term follow-up, whereas the difference in NYHA class was only marginal. Therefore, evaluation of the volumetric response provides information complementary to clinical assessment, especially in predicting long-term clinical outcome after CRT. Because measurement of LV volume was performed off-line in a blinded fashion, the influence of a placebo effect was minimized.
Clinical Implications and Conclusion
The present study established the missing link between the LV reverse remodeling response and long-term clinical outcome after CRT. A reduction in LV volume consistently translated into better clinical outcome, regardless of the modality of therapy (medical or device). The results indicate that LV reverse remodeling 3 to 6 months after CRT not only explains the structural and functional benefits of the resynchronized ventricle but also implies the translation of cardiac structural benefit into a lower clinical "hard" event rate. Of note, improvement in clinical parameters was not predictive of long-term survival. Baseline LV dyssynchrony was predictive of long-term survival, but multivariable analysis identified reverse LV remodeling as the best predictor of long-term survival. Accordingly, the LV reverse-remodeling response is a useful criterion that determines long-term clinical outcome and provides complementary information to clinical parameters such as NYHA class, 6-minute walking distance, or quality-of-life score. Moreover, ROC curve analysis demonstrated that a 10% improvement in LVESV had the best predictive accuracy for long-term survival and may be considered an objective measure to assess clinically useful responses to CRT in future clinical trials.
Limitations of the Study
In this study, the number of events was relatively small. This probably reflects the benefit of CRT in the improvement of clinical outcome, which was recently proven by the CARE-HF study.21 However, with the relatively large number of patients undergoing CRT, we were able to achieve the objective of examining and confirming that LV reverse remodeling is an independent predictor of long-term clinical outcome. Large, multicenter trials are needed to confirm our findings and validate whether a 10% reduction in LVESV is the best volumetric parameter to predict favorable clinical outcome.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001; 344: 873–880.
2. Abraham WT, Fisher WG, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346: 1845–1853.
3. Gras D, Leclercq C, Tang AS, Bucknall C, Luttikhuis HO, Kirstein-Pedersen A. Cardiac resynchronization therapy in advanced heart failure—the multicenter InSync clinical study. Eur J Heart Fail. 2002; 4: 311–320.[CrossRef][Medline] [Order article via Infotrieve]
4. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140–2150.
5. Yu CM, Fung JWH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003; 91: 684–688.[CrossRef][Medline] [Order article via Infotrieve]
6. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003; 107: 1985–1990.
7. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure; SOLVD Investigators. Circulation. 1992; 86: 431–438.
8. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987; 76: 44–51.
9. St John Sutton MG, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994; 89: 68–75.
10. Yu CM, Chau E, Sanderson JE, Fan K, Tang MO, Fung WH, Lin H, Kong SL, Lam YM, Hill MR, Lau CP. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002; 105: 438–445.
11. Stellbrink C, Breithardt OA, Franke A, Sack S, Bakker P, Auricchio A, Pochet T, Salo R, Kramer A, Spinelli J. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol. 2001; 38: 1957–1965.
12. Yu CM, Fung JW, Zhang Q, Chan CK, Chan YS, Lin H, Kum LC, Kong SL, Zhang Y, Sanderson JE. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation. 2004; 110: 66–73.
13. Daubert JC, Ritter P, Le Breton H, Gras D, Leclercq C, Lazarus A, Mugica J, Mabo P, Cazeau S. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol. 1998; 21: 239–245.[CrossRef][Medline] [Order article via Infotrieve]
14. Bax JJ, Marwick TH, Molhoek SG, Bleeker GB, van Erven L, Boersma E, Steendijk P, van der Wall EE, Schalij MJ. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. Am J Cardiol. 2003; 92: 1238–1240.[CrossRef][Medline] [Order article via Infotrieve]
15. Bax JJ, Ansalone G, Breithardt OA, Derumeaux G, Leclercq C, Schalij MJ, Sogaard P, St John Sutton M, Nihoyannopoulos P. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? a critical appraisal. J Am Coll Cardiol. 2004; 44: 1–9.
16. The effect of digoxin on mortality and morbidity in patients with heart failure; the Digitalis Investigation Group. N Engl J Med. 1997; 336: 525–533.
17. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003; 289: 2685–2694.
18. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure; MOCHA Investigators. Circulation. 1996; 94: 2807–2816.[Medline] [Order article via Infotrieve]
19. Remme WJ. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)—rationale and design. Cardiovasc Drugs Ther. 2001; 15: 69–77.[CrossRef][Medline] [Order article via Infotrieve]
20. Reuter S, Garrigue S, Barold SS, Jais P, Hocini M, Haissaguerre M, Clementy J. Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. Am J Cardiol. 2002; 89: 346–350.[CrossRef][Medline] [Order article via Infotrieve]
21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352: 1594–1597.
Related Article:
Circulation 2005 112: 1519.
This article has been cited by other articles:
 |
|
 |
|
  P. Lancellotti, M. Senechal, M. Moonen, E. Donal, J. Magne, E. Nellessen, E. Attena, B. Cosyns, P. Melon, and L. Pierard Myocardial contractile reserve during exercise predicts left ventricular reverse remodelling after cardiac resynchronization therapy Eur J Echocardiogr, July 1, 2009; 10(5): 663 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. J. Gademan, R. J. van Bommel, C. J. W. Borleffs, S. Man, J. C. W. Haest, M. J. Schalij, E. E. van der Wall, J. J. Bax, and C. A. Swenne Biventricular pacing-induced acute response in baroreflex sensitivity has predictive value for midterm response to cardiac resynchronization therapy Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H233 - H237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bax and J. Gorcsan III Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) study in perspective. J. Am. Coll. Cardiol., May 26, 2009; 53(21): 1933 - 1943. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Hawkins, M. C. Petrie, M. I. Burgess, and J. J.V. McMurray Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J. Am. Coll. Cardiol., May 26, 2009; 53(21): 1944 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parsai, B. Bijnens, G. R. Sutherland, A. Baltabaeva, P. Claus, M. Marciniak, V. Paul, M. Scheffer, E. Donal, G. Derumeaux, et al. Toward understanding response to cardiac resynchronization therapy: left ventricular dyssynchrony is only one of multiple mechanisms Eur. Heart J., April 2, 2009; 30(8): 940 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Parsai, A. Baltabaeva, L. Anderson, M. Chaparro, B. Bijnens, and G. R. Sutherland Low-dose dobutamine stress echo to quantify the degree of remodelling after cardiac resynchronization therapy Eur. Heart J., April 2, 2009; 30(8): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Abraham, D. Kass, G. Tonti, G. F. Tomassoni, W. T. Abraham, J. J. Bax, and T. H. Marwick Imaging Cardiac Resynchronization Therapy J. Am. Coll. Cardiol. Img., April 1, 2009; 2(4): 486 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Funaro, G. La Torre, M. Madonna, L. Galiuto, A. Scara, A. Labbadia, E. Canali, A. Mattatelli, F. Fedele, F. Alessandrini, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study Eur. Heart J., March 1, 2009; 30(5): 566 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rivero-Ayerza and B. Schaer Device therapy in heart failure: do all treatment goals apply to all patients? Europace, March 1, 2009; 11(3): 280 - 282. [Full Text] [PDF]
|
|
|
|
|
|
N. Antonio, R. Teixeira, L. Coelho, C. Lourenco, P. Monteiro, M. Ventura, J. Cristovao, L. Elvas, L. Goncalves, and L. A. Providencia Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry Europace, March 1, 2009; 11(3): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ypenburg, R. J. van Bommel, C. J. W. Borleffs, G. B. Bleeker, E. Boersma, M. J. Schalij, and J. J. Bax Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q Zhang, J W-H Fung, J Y-S Chan, G Yip, Y-Y Lam, Y-J Liang, and C-M Yu Difference in long-term clinical outcome after cardiac resynchronisation therapy between ischaemic and non-ischaemic aetiologies of heart failure Heart, January 15, 2009; 95(2): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Landolina, M. Gasparini, M. Lunati, M. Santini, R. Rordorf, A. Vincenti, P. Diotallevi, A. S. Montenero, C. Bonanno, T. De Santo, et al. Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure Eur J Heart Fail, November 1, 2008; 10(11): 1073 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Umar, J. J. Bax, M. Klok, R. J. van Bommel, M. H.M. Hessel, B. den Adel, G. B. Bleeker, M. M. Henneman, D. E. Atsma, E. E. van der Wall, et al. Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy Eur J Heart Fail, September 1, 2008; 10(9): 878 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Kronborg, P. T. Mortensen, R. E. Kirkfeldt, and J. C. Nielsen Very long term follow-up of cardiac resynchronization therapy: Clinical outcome and predictors of mortality Eur J Heart Fail, August 1, 2008; 10(8): 796 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S-A Chang, H-K Kim, H-Y Lee, S-Y Choi, B-K Koo, Y-J Kim, D-W Sohn, B-H Oh, Y-B Park, Y-S Choi, et al. Restoration of left ventricular synchronous contraction after acute myocardial infarction by stem cell therapy: new insights into the therapeutic implication of stem cell therapy for acute myocardial infarction Heart, August 1, 2008; 94(8): 995 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Gradaus, V Stuckenborg, A Loher, J Kobe, F Reinke, S Gunia, C Vahlhaus, G Breithardt, and C Bruch Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy Heart, August 1, 2008; 94(8): 1026 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Lim, G. Y.H. Lip, and J. E. Sanderson Ventricular optimization of biventricular pacing: a systematic review Europace, July 8, 2008; (2008) eun177v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. B. Popovic and J. D. Thomas In Search of a Holy Grail: Predicting Cardiac Resynchronization Therapy Outcomes by Echocardiography Circ Cardiovasc Imaging, July 1, 2008; 1(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
C. Miyazaki, G. Lin, B. D. Powell, R. E. Espinosa, C. J. Bruce, F. A. Miller Jr, B. L. Karon, R. F. Rea, D. L. Hayes, and J. K. Oh Strain Dyssynchrony Index Correlates With Improvement in Left Ventricular Volume After Cardiac Resynchronization Therapy Better Than Tissue Velocity Dyssynchrony Indexes Circ Cardiovasc Imaging, July 1, 2008; 1(1): 14 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gasparini, A. Auricchio, M. Metra, F. Regoli, C. Fantoni, B. Lamp, A. Curnis, J. Vogt, C. Klersy, and for the Multicentre Longitudinal Observational Stu Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation Eur. Heart J., July 1, 2008; 29(13): 1644 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Khadjooi, P W Foley, S Chalil, J Anthony, R E A Smith, M P Frenneaux, and F Leyva Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation Heart, July 1, 2008; 94(7): 879 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Sweeney and F. W. Prinzen Ventricular Pump Function and Pacing: Physiological and Clinical Integration Circ Arrhythmia Electrophysiol, June 1, 2008; 1(2): 127 - 139. [Full Text] [PDF]
|
|
|
|
|
|
L. Di Biase, A. Auricchio, A. Sorgente, K. Civello, C. Klersy, F. Faletra, L. Riedlbauchova, D. Patel, M. Arruda, R. A. Schweikert, et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy Eur. Heart J., May 30, 2008; (2008) ehn221v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vitarelli Echocardiographic selection of candidates for cardiac resynchronization therapy: the lack of evidence! Reply Eur J Echocardiogr, May 1, 2008; 9(3): 320 - 321. [Full Text] [PDF]
|
|
|
|
|
|
C. Leclercq, F. Gadler, W. Kranig, S. Ellery, D. Gras, A. Lazarus, J. Clementy, E. Boulogne, J.-C. Daubert, and for the TRIP-HF (Triple Resynchronization In Paced A Randomized Comparison of Triple-Site Versus Dual-Site Ventricular Stimulation in Patients With Congestive Heart Failure J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1455 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J L Hare, C Jenkins, S Nakatani, A Ogawa, C-M Yu, and T H Marwick Feasibility and clinical decision-making with 3D echocardiography in routine practice Heart, April 1, 2008; 94(4): 440 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W.L. De Boeck, M. Meine, G. E. Leenders, A. J. Teske, H. van Wessel, J. H. Kirkels, F. W. Prinzen, P. A. Doevendans, and M. J. Cramer Practical and conceptual limitations of tissue Doppler imaging to predict reverse remodelling in cardiac resynchronisation therapy Eur J Heart Fail, March 1, 2008; 10(3): 281 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Nagueh Mechanical dyssynchrony in congestive heart failure: diagnostic and therapeutic implications. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 18 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B Bleeker, C.-M. Yu, P. Nihoyannopoulos, J. de Sutter, N. Van de Veire, E. R Holman, M. J Schalij, E. E van der Wall, and J. J Bax Optimal use of echocardiography in cardiac resynchronisation therapy Heart, November 1, 2007; 93(11): 1339 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gorcsan III, M. Tanabe, G. B. Bleeker, M. S. Suffoletto, N. C. Thomas, S. Saba, L. F. Tops, M. J. Schalij, and J. J. Bax Combined Longitudinal and Radial Dyssynchrony Predicts Ventricular Response After Resynchronization Therapy J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1476 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H.M. Hessel, G. B. Bleeker, J. J. Bax, M. M. Henneman, B. den Adel, M. Klok, M.J. Schalij, D. E. Atsma, and A. van der Laarse Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail, October 1, 2007; 9(10): 1058 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Europace, October 1, 2007; 9(10): 959 - 998. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass Highlighting the R in CRT Circulation, September 25, 2007; 116(13): 1434 - 1436. [Full Text] [PDF]
|
|
|
|
|
|
G. B. Bleeker, S. A. Mollema, E. R. Holman, N. Van De Veire, C. Ypenburg, E. Boersma, E. E. van der Wall, M. J. Schalij, and J. J. Bax Left Ventricular Resynchronization Is Mandatory for Response to Cardiac Resynchronization Therapy: Analysis in Patients With Echocardiographic Evidence of Left Ventricular Dyssynchrony at Baseline Circulation, September 25, 2007; 116(13): 1440 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Eur. Heart J., September 2, 2007; 28(18): 2256 - 2295. [Full Text] [PDF]
|
|
|
|
|
|
K. Vernooy, R. N.M. Cornelussen, X. A.A.M. Verbeek, W. Y.R. Vanagt, A. van Hunnik, M. Kuiper, T. Arts, H. J.G.M. Crijns, and F. W. Prinzen Cardiac resynchronization therapy cures dyssynchronopathy in canine left bundle-branch block hearts Eur. Heart J., September 1, 2007; 28(17): 2148 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cabrera-Bueno, J. M. Garcia-Pinilla, J. Pena-Hernandez, M. Jimenez-Navarro, J. J. Gomez-Doblas, A. Barrera-Cordero, J. Alzueta-Rodriguez, and E. de Teresa-Galvan Repercussion of functional mitral regurgitation on reverse remodelling in cardiac resynchronization therapy Europace, September 1, 2007; 9(9): 757 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-M. Yu, F. Fang, Q. Zhang, G. W.K. Yip, C. M. Li, J. Y.-S. Chan, L. Wu, and J. W.-H. Fung Improvement of Atrial Function and Atrial Reverse Remodeling After Cardiac Resynchronization Therapy for Heart Failure J. Am. Coll. Cardiol., August 21, 2007; 50(8): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Doughty, K. Poppe, and J. Stewart Predicting outcome in severe heart failure. Who will benefit from device therapy (CRT)? Eur. Heart J., August 1, 2007; 28(15): 1790 - 1792. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Kirkpatrick, M. A. Vannan, J. Narula, and R. M. Lang Echocardiography in Heart Failure: Applications, Utility, and New Horizons J. Am. Coll. Cardiol., July 31, 2007; 50(5): 381 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chalil, B. Stegemann, S. Muhyaldeen, K. Khadjooi, R. E.A. Smith, P. J. Jordan, and F. Leyva Intraventricular Dyssynchrony Predicts Mortality and Morbidity After Cardiac Resynchronization Therapy: A Study Using Cardiovascular Magnetic Resonance Tissue Synchronization Imaging J. Am. Coll. Cardiol., July 17, 2007; 50(3): 243 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, J. Ezekowitz, N. Hooton, B. Vandermeer, C. Spooner, D. M. Dryden, R. L. Page, M. A. Hlatky, and B. H. Rowe Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction: A Systematic Review JAMA, June 13, 2007; 297(22): 2502 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-M. Yu, J. E. Sanderson, T. H. Marwick, and J. K. Oh Tissue Doppler Imaging: A New Prognosticator for Cardiovascular Diseases J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1903 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Tournoux, C. Alabiad, D. Fan, A. A. Chen, M. Chaput, E. K. Heist, T. Mela, M. Mansour, V. Reddy, J. N. Ruskin, et al. Echocardiographic measures of acute haemodynamic response after cardiac resynchronization therapy predict long-term clinical outcome Eur. Heart J., May 1, 2007; 28(9): 1143 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W H Fung, J. Y S Chan, G. W K Yip, H. C K Chan, W. W L Chan, Q. Zhang, and C.-M. Yu Effect of left ventricular endocardial activation pattern on echocardiographic and clinical response to cardiac resynchronization therapy Heart, April 1, 2007; 93(4): 432 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C-M Yu, Q Zhang, Y-S Chan, C-K Chan, G W K Yip, L C C Kum, E B Wu, P-W Lee, Y-Y Lam, S Chan, et al. Tissue Doppler velocity is superior to displacement and strain mapping in predicting left ventricular reverse remodelling response after cardiac resynchronisation therapy Heart, October 1, 2006; 92(10): 1452 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gasparini, A. Auricchio, F. Regoli, C. Fantoni, M. Kawabata, P. Galimberti, D. Pini, C. Ceriotti, E. Gronda, C. Klersy, et al. Four-Year Efficacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease Progression: The Importance of Performing Atrioventricular Junction Ablation in Patients With Atrial Fibrillation J. Am. Coll. Cardiol., August 15, 2006; 48(4): 734 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, J. W.-H. Fung, A. Auricchio, J. Y.-S. Chan, L. C.C. Kum, L. W. Wu, and C.-M. Yu Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure Eur. Heart J., June 2, 2006; 27(12): 1423 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mannaerts Regression of left ventricular mass and wall thickness after cardiac resynchronization therapy: proof of pathophysiological concept Eur. Heart J., June 2, 2006; 27(12): 1392 - 1393. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Scheinman and E. Keung The Year in Clinical Electrophysiology J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1207 - 1213. [Full Text] [PDF]
|
|
|
|
|
|
F. A Flachskampf and J.-U. Voigt Echocardiographic methods to select candidates for cardiac resynchronisation therapy. Heart, March 1, 2006; 92(3): 424 - 429. [Full Text] [PDF]
|
|
|
|
|
|
A. E. Weyman The Year in Echocardiography J. Am. Coll. Cardiol., February 21, 2006; 47(4): 856 - 863. [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||